Partnership insights
Collaborating, innovating, and finding new ways together to improve outcomes
Much more can be achieved when all players in the life sciences and pharmaceutical industries work together, in a truly collaborative way. At ICON, this means working in a way that goes beyond a traditional CRO. It means being a trusted partner.
Exploring partnership culture and its impact on outsourcing and operational strategy
Partnership culture within the clinical research industry has often been overlooked as a component of a successful outsourcing strategy. However, culture can support, inform, and maintain strategies and operational decision-making.
Webinar: Exploring partnership culture and its impact on outsourcing and operational strategy
In this webinar, Sanofi and ICON discuss how they created a shared partnership/alliance culture, which has evolved both the outsourcing strategy and operating model. Attendees will learn about the specific tools and methods used to develop and support the Sanofi / ICON partnership, including:
- Adaptation of the 9 Box Grid to assess cultural alignment and outsourcing and operational strategy, identifying areas of strength and opportunities for development
- An “ABCs of Culture” framework, designed to build cross-organisational cultural alignment.
The evolving relationship between sponsors and CROs
In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.
Sponsor and CRO pharmacovigilance and safety alliances
This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.
Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
Engaging physicians to support and increase clinical research activity
More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.
-
Media article: LEO Pharma and ICON plc collaborate to improve outcomes for dermatology patients
This article, published on Outsourcing Pharma, covers the strategic partnership between LEO Pharma and ICON.
-
Media article: LEO Pharma and ICON partner for clinical trial execution in dermatology
This news article outlines how the collaboration is expected to provide access to innovative clinical trials as well as help to launch new medicines.
-
Media article: LEO Pharma and ICON enter strategic partnership
LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective.
-
Media article: ICON and LEO Pharma join forces on clinical trial mission
This news article, published on PharmaTimes online, indicates how the collaboration will concentrate on launching and running studies within medical dermatology.
-
Media article: LEO Pharma, ICON partner to advance clinical trials in dermatology
This news article covers the strategic partnership between LEO Pharma and ICON to propel clinical trial execution within medical dermatology.
-
Media article: The power of partnership: Collaborating with patient advocacy organisations for better clinical research
Laura Iliescu explores the powerful potential of collaboration with PAOs for clinical trials, particularly how PAOs can inform trial design and the creation of patient re
-
Media article: The evolving relationship between sponsors and contract research organisations
Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services.
-
Media article: Redefining CRO sourcing model terminology to optimise outsourcing strategies
Samir Shah, President, Strategic Solutions at ICON contributes to this Applied Clinical Trials article discussing the compelling need for new terminology for sourcing models in the CRO industry.